Navigation Links
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Date:11/26/2007

PRINCETON, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) appointed Patrick T. Higgins as Executive Vice President, Marketing & Sales, responsible for coordinating the global product launch and marketing activities for Pharmasset's drug candidates. Mr. Higgins, who has served as a consultant to Pharmasset since 2006, was recently Vice President, Sales & Marketing, Virology at Hoffmann-LaRoche, Inc. His areas of expertise include hepatology, HIV and cytomegalovirus for transplant patients. Mr. Higgins was responsible for directing the development and implementation of marketing and sales plans for Roche's US hepatology franchise, including the global launch of Pegasys(R) and Copegus(R) for the treatment of chronic hepatitis C infection.

Mr. Higgins has over 25 years of pharmaceutical industry sales and marketing experience. Throughout his career, he has participated in a total of 13 product launches for antiviral, oncology, dermatologic and allergy indications. Prior to joining Roche, Mr. Higgins served in a variety of advertising, sales and marketing roles at Schering Corporation. He was instrumental in developing Schering's Oncology/Biotech group that launched Intron-A(R) (interferon alfa-2b) for the treatment of chronic hepatitis.

"I am delighted to join Pharmasset at this stage of its development," stated Mr. Higgins. "I see the same characteristics and potential in Pharmasset's science, drug candidates and people that I saw in both Roche and Schering prior to their successful product launches."

"Pharmasset intends to commercialize clevudine for the treatment of chronic hepatitis B infection," stated Schaefer Price, Pharmasset's President & CEO. "To accomplish this goal, we plan to capitalize on Patrick's extensive experience in the field of hepatology, his personal relationships with key opinion leaders and his proven ability to build successful marketing and sales organizations."

Mr. Higgins received his M.B.A. from Seton Hall University and his Bachelor of Arts from Villanova University.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, being developed for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for product registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, being developed as an oral treatment for chronic HCV infection, is enrolling a 4- week Phase 1 clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) through a strategic collaboration with Roche. Racivir, being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. Intron-A(R) is a registered trademark of Schering Corporation.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Novo Nordisk Appoints New Leader of North American Business
5. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. Resonant Medical Appoints New Vice President of Global Sales
9. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 20, 2017 , ... ChenMed , a leading provider of value-based care ... Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of ... Officer of Ambulatory Services for the UVA Health System, brings 30 years of highly ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse. With such a challenging diagnosis that requires immediate action, patients ...
(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
Breaking Medicine Technology: